You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

alemtuzumab

Showing 1 - 25 of 145
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Allogeneic Hematopoietic Cell Transplantation Trial (Alemtuzumab)

Not yet recruiting
  • Allogeneic Hematopoietic Cell Transplantation
  • Alemtuzumab
  • (no location specified)
Aug 12, 2022

CLL, SLL Trial in Boston (Ofatumumab, High-Dose Methylprednisolone, Alemtuzumab)

Terminated
Has Results
  • CLL
  • SLL
  • Boston, Massachusetts
  • +1 more
Jan 30, 2023

T-cell-prolymphocytic Leukemia Trial in Cologne (Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab, Alemtuzumab)

Completed
  • T-cell-prolymphocytic Leukemia
  • Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab
  • Alemtuzumab
  • Cologne, Germany
    University Hospital Cologne
Dec 16, 2021

Chronic Granulomatous Disease Trial run by the NIAID (Sirolimus, Cyclophosphamide, Alemtuzumab)

Recruiting
  • Chronic Granulomatous Disease
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 23, 2022

Leukemia Trial in Houston (Alemtuzumab, Etoposide, Dexamethasone)

Active, not recruiting
  • Leukemia
  • Alemtuzumab
  • +5 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Feb 2, 2022

Relapsing-Remitting Multiple Sclerosis Trial in Hamburg, Mannheim (Autologous Hematopoietic Stem Cell Transplantation,

Terminated
  • Relapsing-Remitting Multiple Sclerosis
  • Autologous Hematopoietic Stem Cell Transplantation
  • +2 more
  • Hamburg, Germany
  • +1 more
Mar 1, 2022

Multiple Sclerosis (MS) Trial in Dallas (Alemtuzumab)

Completed
Has Results
  • Multiple Sclerosis (MS)
  • Alemtuzumab
  • Dallas, Texas
  • +1 more
Jan 24, 2022

Leukemia, Lymphocytic, Chronic, B-Cell Trial in Austria (Bendamustine, Alemtuzumab)

Completed
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Innsbruck, Tirol, Austria
  • +6 more
Feb 15, 2022

Multiple Sclerosis, Relapsing-Remitting Trial in Münster (Alemtuzumab)

Completed
  • Multiple Sclerosis, Relapsing-Remitting
  • Alemtuzumab
  • Münster, Germany
    Universitätsklinikum Münster, Klinik für Allgemeine Neurologie
Oct 25, 2021

Sickle Cell Disease Trial in Duarte (drug, procedure, radiation)

Recruiting
  • Sickle Cell Disease
  • Alemtuzumab
  • +3 more
  • Duarte, California
    City of Hope Comprehensive Cancer Center
Jul 31, 2022

Sickle Cell Disease Trial in Hackensack (Alemtuzumab, Fludarabine, Melphalan)

Active, not recruiting
  • Sickle Cell Disease
  • Alemtuzumab
  • +3 more
  • Hackensack, New Jersey
    Hackensack University Medical Center
Feb 4, 2022

Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Recruiting
  • Multiple Sclerosis
  • Diroximel Fumarate
  • +8 more
  • Eden Prairie, Minnesota
    OptumInsight
Jan 9, 2023

Secondary Malignant Tumor of Retroperitoneum, Secondary Malignant Tumor of Peritoneum, Pseudomyxoma Peritonei Trial in Cleveland

Not yet recruiting
  • Secondary Malignant Neoplasm of Retroperitoneum
  • +2 more
  • Intestinal, Multivisceral or Modified Multivisceral Transplantation
  • +3 more
  • Cleveland, Ohio
    Cleveland Clinic Digestive Disease & Surgery Institute (DDSI), C
Oct 10, 2023

Sickle Cell Anemia Trial run by the NHLBI (PBSC Transplant, Alemtuzumab, Sirolimus)

Active, not recruiting
Has Results
  • Sickle Cell Anemia
  • PBSC Transplant
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Oct 13, 2022

Neurofilaments for NEDA Assessing in MS

Terminated
  • Multiple Sclerosis
  • Alemtuzumab
  • London, England, United Kingdom
    Queen Mary University of London
Feb 9, 2022

Acute Undifferentiated Leukemia, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia Trial

Completed
Has Results
  • Acute Undifferentiated Leukemia
  • +13 more
  • Chicago, Illinois
    Cancer and Leukemia Group B
Apr 5, 2022

Chronic Granulomatous Disease Transplant Trial run by the NIAID (drug, radiation, biological)

Active, not recruiting
  • Chronic Granulomatous Disease Transplant
  • Alemtuzumab
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 21, 2023

Sickle Cell Anemia, Beta Thalassemia Trial run by the NHLBI (radiation, drug, biological)

Recruiting
  • Sickle Cell Anemia
  • Beta Thalassemia
  • TBI
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2023

Congenital Hemolytic Anemia, Sickle Cell Disease Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (Peripheral

Recruiting
  • Congenital Hemolytic Anemia
  • Sickle Cell Disease
  • Peripheral blood hematopoietic progenitor cell (PBPC) transplant
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases Trial run by the NCI (drug, radiation,

Recruiting
  • Lymphoproliferative Disorders
  • +4 more
  • Busulfan test dose
  • +8 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Hemophagocytic Lymphohistiocytosis (HLH) Trial in Paris (Alemtuzumab, Methyl Prednisolone (MP), Cyclosporin A (CSA))

Completed
  • Hemophagocytic Lymphohistiocytosis (HLH)
  • Alemtuzumab
  • +2 more
  • Paris, France
    Hôpital Necker-Enfants Malades
Apr 13, 2021

Sickle Cell Disease, Thalassemia, Stem Cell Transplantation Trial run by the National Heart, Lung, and Blood Institute (NHLBI)

Recruiting
  • Sickle Cell Disease
  • +3 more
  • Alemtuzumab
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Primary Immune Deficiency Disorder, Immune Deficiency Disease, Bone Marrow Failure Trial in Baltimore (Alemtuzumab, Fludarabine,

Recruiting
  • Primary Immune Deficiency Disorder
  • +2 more
  • Alemtuzumab
  • +6 more
  • Baltimore, Maryland
    Johns Hopkins University
Oct 20, 2022

Sickle Cell Disease Trial in Saint Louis (drug, radiation, procedure)

Terminated
  • Sickle Cell Disease
  • Alemtuzumab
  • +6 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 28, 2022

Sickle Cell Disease Trial in Chicago (Allogeneic Non-Myeloablative Stem Cell Transplantation, Alemtuzumab, Sirolimus)

Recruiting
  • Sickle Cell Disease
  • Allogeneic Non-Myeloablative Stem Cell Transplantation
  • +2 more
  • Chicago, Illinois
    University of Illinois at Chicago
Feb 16, 2022